Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Clinical_Trials
|
| gptkbp:advocacy |
informed consent obtained
|
| gptkbp:affects |
assessed long-term effects of treatment
|
| gptkbp:analysis |
statistical methods used
|
| gptkbp:business_model |
approved by ethics committees
|
| gptkbp:clinical_implications |
implications for clinical practice
|
| gptkbp:clinical_trial |
demonstrated clinical significance
registered in clinical trial databases |
| gptkbp:collaboration |
international research teams
|
| gptkbp:collaborations |
collaborated with academic institutions
|
| gptkbp:collection |
clinical assessments
|
| gptkbp:community |
contributed to scientific community knowledge
|
| gptkbp:criteria |
other neurological disorders
adults with relapsing forms of MS |
| gptkbp:diseases |
gptkb:multiple_sclerosis
|
| gptkbp:duration |
up to 2 years
24 weeks |
| gptkbp:feedback |
collected patient feedback during trial
|
| gptkbp:follow-up_period |
up to 5 years
|
| gptkbp:funding |
funded by pharmaceutical company
|
| gptkbp:future_prospects |
suggested areas for future research
|
| gptkbp:has_limitations |
acknowledged limitations in study
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ult IMMa-2
|
| gptkbp:impact |
significant impact on MS treatment strategies
treatment guidelines for MS |
| gptkbp:investigator_sites |
multiple clinical sites involved
|
| gptkbp:is_compared_to |
placebo
|
| gptkbp:is_monitored_by |
regular monitoring of patients
|
| gptkbp:is_studied_in |
multicenter study
|
| gptkbp:is_tested_for |
Phase III
|
| gptkbp:location |
multiple countries
|
| gptkbp:notable_work |
contributed to MS research
|
| gptkbp:objective |
focused on treatment efficacy and safety
|
| gptkbp:participants |
disability progression
efficacy of ocrelizumab safety of ocrelizumab |
| gptkbp:patient_population |
diverse population
adults aged 18-55 |
| gptkbp:primary_investigator |
lead researcher name
|
| gptkbp:provides_guidance_on |
administered every 6 months
influenced clinical guidelines for MS management |
| gptkbp:provides_information_on |
data shared with research community
|
| gptkbp:publication |
published in medical journals
|
| gptkbp:publication_year |
gptkb:2020
|
| gptkbp:regulatory_compliance |
FDA approval
|
| gptkbp:research_output |
published in peer-reviewed journals
improved understanding of MS treatment |
| gptkbp:research_transparency |
promoted research transparency
|
| gptkbp:result |
positive efficacy results
|
| gptkbp:safety_features |
favorable safety profile
|
| gptkbp:sampled_in |
randomized controlled trial
|
| gptkbp:security |
ensured data integrity throughout study
|
| gptkbp:side_effect |
monitored throughout the trial
|
| gptkbp:sponsor |
gptkb:Roche
|
| gptkbp:start_date |
gptkb:2015
|
| gptkbp:student_enrollment |
approximately 2000 participants
|
| gptkbp:study_outcomes |
measured using standardized scales
|
| gptkbp:treatment |
gptkb:ocrelizumab
evaluated patient outcomes post-treatment |
| gptkbp:vision |
double-blind study
|
| gptkbp:year |
gptkb:2019
|
| gptkbp:bfsParent |
gptkb:Skyrizi
|
| gptkbp:bfsLayer |
5
|